NEW YORK (GenomeWeb News) – Transgenomic believes that a new PCR technology that it recently licensed from the Dana-Farber Cancer Institute could have promise down the road as a screening tool to detect early-stage cancer in blood samples.

The technology, called coamplification at lower denaturation temperature PCR, or COLD-PCR, was developed by Mike Makrigiorgos' lab at Dana-Farber. It preferentially amplifies segments of DNA that contain mutations, and is thereby able to increase the sensitivity of downstream mutation-detection methods by a factor of 10 to 100.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.